Management of COPD symptoms: the role of mucolytics

View Article
01 February 2022
Management of COPD symptoms: the role of mucolytics

Author

Terry Robinson
Terry Robinson
Respiratory Nurse - Consultant Harrogate and District NHS Foundation Trust

Introduction

Chronic obstructive pulmonary disease (COPD) affects up to three million people in the UK.  Sputum production is a common feature of COPD but for some patients it is difficult to clear, leaving them potentially vulnerable to respiratory infections. This article looks at the evidence for mucolytic therapies and when they should be considered.

OVERVIEW

COPD is a common condition in the UK, with many patients living with symptoms and disability which have not been brought to the attention of a healthcare professional.

This article reviews the background to COPD and its current management guidelines.

It goes on to review the mechanisms of mucous production in COPD and examines the evidence for different treatment choices.

Case studies are used to explore a variety of real-world challenges associated with the management of this important and debilitating condition.

ARTICLE LINK

Practice Nurse – Mucolytics Supplement

Trust in our products

The products at the heart of our portfolio have been licensed in the UK for almost fifty years, and have been used up and down the country to help countless patients during that period. We continue to treat these important products with the care and respect that they deserve.